A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 19 Oct 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary)
- Indications Ewing's sarcoma; Lymphoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 29 Jul 2019 Planned End Date changed from 30 Dec 2022 to 25 May 2023.
- 29 Jul 2019 Planned primary completion date changed from 21 Apr 2022 to 3 Jan 2023.
- 24 Jun 2019 Planned End Date changed from 24 Aug 2021 to 30 Dec 2022.